Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Scientific reports [Sci Rep] NLMUID: 101563288"" wg kryterium: JN


Tytuł :
DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition.
Autorzy :
Viera T; Department of Chemistry, New Mexico Institute of Mining and Technology, 801 Leroy Pl, Socorro, NM, 87801, USA.
Patidar PL; Department of Chemistry, New Mexico Institute of Mining and Technology, 801 Leroy Pl, Socorro, NM, 87801, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Nov 19; Vol. 10 (1), pp. 20210. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents/*pharmacology
Cell Survival/*drug effects
DNA Damage/*drug effects
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Pancreatic Neoplasms/*drug therapy
Poly (ADP-Ribose) Polymerase-1/*metabolism
Tetrazoles/*pharmacology
Antineoplastic Agents/therapeutic use ; Cell Death/drug effects ; Cell Line, Tumor ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; NAD(P)H Dehydrogenase (Quinone)/metabolism ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Reactive Oxygen Species/metabolism ; Tetrazoles/therapeutic use
Czasopismo naukowe
Tytuł :
Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy.
Autorzy :
Yoo JD; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Bae SM; PrismCDX, Inc., 593-16, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do, 18469, Republic of Korea.
Seo J; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Jeon IS; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Vadevoo SMP; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Kim SY; Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138-736, Republic of Korea.; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Kim IS; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
Lee B; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
Kim S; Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Nov 17; Vol. 10 (1), pp. 19997. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*chemistry
Antineoplastic Agents/*pharmacology
Ferritins/*chemistry
Nanostructures/*chemistry
Peptides/*chemistry
TNF-Related Apoptosis-Inducing Ligand/*chemistry
TNF-Related Apoptosis-Inducing Ligand/*metabolism
A549 Cells ; Animals ; Apoptosis/drug effects ; Breast Neoplasms/drug therapy ; Cell Line, Tumor ; Female ; Humans ; Interleukin-4 Receptor alpha Subunit/metabolism ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Pancreatic Neoplasms/drug therapy ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays/methods
SCR Disease Name :
Pancreatic Carcinoma
Czasopismo naukowe
Tytuł :
Preparation, characterization and therapeutic properties of gum arabic-stabilized gallic acid nanoparticles.
Autorzy :
Hassani A; Department of Chemical and Environmental Engineering, Faculty of Engineering, Universiti Putra Malaysia, Serdang, UPM, Serdang, 43400, Malaysia.
Azarian MMS; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, UPM, Serdang, 43400, Malaysia.
Ibrahim WN; Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. .
Hussain SA; Department of Chemical and Environmental Engineering, Faculty of Engineering, Universiti Putra Malaysia, Serdang, UPM, Serdang, 43400, Malaysia. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 20; Vol. 10 (1), pp. 17808. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiotensin-Converting Enzyme Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Antioxidants/*pharmacology
Epithelial Cells/*physiology
Gallic Acid/*pharmacology
Hypertension/*drug therapy
Neoplasms/*drug therapy
Angiotensin-Converting Enzyme Inhibitors/chemistry ; Antineoplastic Agents/chemistry ; Antioxidants/chemistry ; Apoptosis ; Biphenyl Compounds ; Cell Movement ; Epithelial Cells/drug effects ; Gallic Acid/chemistry ; Gum Arabic/chemistry ; HT29 Cells ; Hep G2 Cells ; Humans ; MCF-7 Cells ; Nanoparticles/chemistry ; Nitric Oxide/metabolism ; Picrates
Czasopismo naukowe
Tytuł :
Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
Autorzy :
Tsai LH; Research Center for Cancer Biology, China Medical University, No. 91, Hsueh-Shih Road, North District, Taichung, Taiwan.; Drug Development Center, China Medical University, Taichung, Taiwan.
Hsu KW; Research Center for Cancer Biology, China Medical University, No. 91, Hsueh-Shih Road, North District, Taichung, Taiwan.; Drug Development Center, China Medical University, Taichung, Taiwan.; Institute of New Drug Development, China Medical University, Taichung, Taiwan.
Chiang CM; Department of Pharmacology, and Department of Biochemistry, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
Yang HJ; Research Center for Cancer Biology, China Medical University, No. 91, Hsueh-Shih Road, North District, Taichung, Taiwan.
Liu YH; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Yang SF; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Peng PH; Cancer Genome Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Cheng WC; Research Center for Cancer Biology, China Medical University, No. 91, Hsueh-Shih Road, North District, Taichung, Taiwan.; Drug Development Center, China Medical University, Taichung, Taiwan.; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Wu HH; Research Center for Cancer Biology, China Medical University, No. 91, Hsueh-Shih Road, North District, Taichung, Taiwan. .; Drug Development Center, China Medical University, Taichung, Taiwan. .; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 20; Vol. 10 (1), pp. 17817. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Blocking/*therapeutic use
Antineoplastic Agents/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Deoxycytidine/*analogs & derivatives
Neoplastic Stem Cells/*physiology
Pancreatic Neoplasms/*drug therapy
Receptors, Interleukin-17/*metabolism
Deoxycytidine/therapeutic use ; Down-Regulation ; Drug Resistance ; Drug Synergism ; Drug Therapy, Combination ; Humans ; Molecular Targeted Therapy ; Mucins/metabolism ; Receptors, Interleukin-17/genetics ; Receptors, Interleukin-17/immunology ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Autorzy :
Areeb Z; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Stuart SF; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
West AJ; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Gomez J; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Nguyen HPT; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Paradiso L; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Zulkifli A; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Jones J; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Kaye AH; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Neurosurgery, Hadassah Hebrew University Medical Centre, 91120, Jerusalem, Israel.
Morokoff AP; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.
Luwor RB; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 20; Vol. 10 (1), pp. 17768. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Brain Neoplasms/*drug therapy
Chemoradiotherapy/*methods
Glioblastoma/*drug therapy
MicroRNAs/*genetics
Temozolomide/*pharmacology
Apoptosis ; Brain Neoplasms/genetics ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Gene Expression Regulation, Neoplastic ; Glioblastoma/genetics ; Humans ; Neoplasm Recurrence, Local ; Signal Transduction
Czasopismo naukowe
Tytuł :
Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism.
Autorzy :
O'Leary BR; Department of Surgery, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Alexander MS; Department of Surgery, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Du J; Department of Surgery, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Moose DL; Department of Molecular Physiology and Biophsics, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Henry MD; Department of Molecular Physiology and Biophsics, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.; The Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, The University of Iowa Carver College of Medicine, 1528 JCP, 200 Hawkins Drive, Iowa City, IA, 52242, USA.; Department of Pathology, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.; Department of Urology, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.; Free Radical and Radiation Biology Program, Department of Radiation Oncology, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Cullen JJ; Department of Surgery, The University of Iowa Carver College of Medicine, Iowa City, IA, USA. .; The Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, The University of Iowa Carver College of Medicine, 1528 JCP, 200 Hawkins Drive, Iowa City, IA, 52242, USA. .; Free Radical and Radiation Biology Program, Department of Radiation Oncology, The University of Iowa Carver College of Medicine, Iowa City, IA, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 19; Vol. 10 (1), pp. 17649. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Ascorbic Acid/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Peroxides/*metabolism
Animals ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/metabolism ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor ; Female ; Humans ; Hydrogen Peroxide/metabolism ; Liver Neoplasms/secondary ; Mice ; Mice, Nude ; Neoplasm Metastasis/drug therapy ; Neoplasm Transplantation ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Neoplastic Cells, Circulating/drug effects ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Gap between pediatric and adult approvals of molecular targeted drugs.
Autorzy :
Nishiwaki S; Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan. .
Ando Y; Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 13; Vol. 10 (1), pp. 17145. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Drug Approval/*legislation & jurisprudence
Neoplasms/*drug therapy
Adult ; Child ; European Union ; Humans ; Japan ; Molecular Targeted Therapy/methods ; United States ; United States Food and Drug Administration/legislation & jurisprudence
Czasopismo naukowe
Tytuł :
Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells.
Autorzy :
Barkovskaya A; Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway.; Department of Tumor Biology, Institute for Cancer Research, Radiumhospital, Oslo University Hospital, Oslo, Norway.; Department of Surgery, University of California San Francisco, California, USA.
Seip K; Department of Tumor Biology, Institute for Cancer Research, Radiumhospital, Oslo University Hospital, Oslo, Norway.
Prasmickaite L; Department of Tumor Biology, Institute for Cancer Research, Radiumhospital, Oslo University Hospital, Oslo, Norway.
Mills IG; Centre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 0349, Oslo, Norway.; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK.
Moestue SA; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Health Sciences, Nord University, Bodø, Norway.
Itkonen HM; Centre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 0349, Oslo, Norway. .; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 12; Vol. 10 (1), pp. 16992. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
N-Acetylglucosaminyltransferases/*metabolism
Tamoxifen/*therapeutic use
Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; Breast Neoplasms/mortality ; Drug Resistance, Neoplasm ; ErbB Receptors/metabolism ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; MCF-7 Cells ; N-Acetylglucosaminyltransferases/genetics ; RNA, Small Interfering/genetics ; Signal Transduction ; Survival Analysis ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; Unfolded Protein Response
Czasopismo naukowe
Tytuł :
Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer.
Autorzy :
Smith T; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 1415 South Martin Luther King Blvd, Tallahassee, FL, 32307, USA.
Affram K; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 1415 South Martin Luther King Blvd, Tallahassee, FL, 32307, USA.
Nottingham EL; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 1415 South Martin Luther King Blvd, Tallahassee, FL, 32307, USA.
Han B; Department of Surgery, Keck School of Medicine University of Southern California, Los Angeles, CA, USA.
Amissah F; College of Pharmacy, Ferris State University, Big Rapids, MI, USA.
Krishnan S; Mayo Clinic, Jacksonville, FL, USA.
Trevino J; Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.
Agyare E; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 1415 South Martin Luther King Blvd, Tallahassee, FL, 32307, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 12; Vol. 10 (1), pp. 16989. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Drug Delivery Systems/*methods
Fluorouracil/*therapeutic use
Liposomes/*therapeutic use
Nanoparticles/*therapeutic use
Animals ; Apoptosis ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; HCT116 Cells ; Humans ; Mice ; Mice, SCID ; Neoplasm Transplantation ; Receptor, ErbB-2/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study.
Autorzy :
Kaneda H; Osaka City University, Osaka, Japan.
Kizaki M; Novartis Pharma K.K., Tokyo, Japan.
Ochi M; Novartis Pharma K.K., Tokyo, Japan.
Shiraiwa N; Novartis Pharma K.K., Tokyo, Japan.
Akatsu S; Novartis Pharma K.K., Tokyo, Japan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16773. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Sulfones/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/metabolism ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Lung Neoplasms/enzymology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Product Surveillance, Postmarketing ; Progression-Free Survival ; Pyrimidines/adverse effects ; Sulfones/adverse effects
Czasopismo naukowe
Tytuł :
Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery.
Autorzy :
Tsou LK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Yeh SH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Ueng SH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Chang CP; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Song JS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Wu MH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Chang HF; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Chen SR; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Shih C; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Chen CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC.
Ke YY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, 35053, Miaoli County, Taiwan, ROC. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16771. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Deep Learning*
Antineoplastic Agents/*therapeutic use
Receptors, G-Protein-Coupled/*agonists
Triple Negative Breast Neoplasms/*drug therapy
Algorithms ; Drug Discovery/methods ; Humans ; Neural Networks, Computer
Czasopismo naukowe
Tytuł :
Synthesis and structure of a new thiazoline-based palladium(II) complex that promotes cytotoxicity and apoptosis of human promyelocytic leukemia HL-60 cells.
Autorzy :
Espino J; Department of Physiology (Neuroimmunophysiology and Chrononutrition Research Group), Faculty of Science, University of Extremadura, 06006, Badajoz, Spain.
Fernández-Delgado E; Department of Physiology (Neuroimmunophysiology and Chrononutrition Research Group), Faculty of Science, University of Extremadura, 06006, Badajoz, Spain.
Estirado S; Department of Physiology (Neuroimmunophysiology and Chrononutrition Research Group), Faculty of Science, University of Extremadura, 06006, Badajoz, Spain.
de la Cruz-Martinez F; Departament of Organic and Inorganic Chemistry (Chemistry of Coordination Research Group), Faculty of Science, University of Extremadura, Badajoz, Spain.
Villa-Carballar S; Department of Physiology (Neuroimmunophysiology and Chrononutrition Research Group), Faculty of Science, University of Extremadura, 06006, Badajoz, Spain.
Viñuelas-Zahínos E; Departament of Organic and Inorganic Chemistry (Chemistry of Coordination Research Group), Faculty of Science, University of Extremadura, Badajoz, Spain.
Luna-Giles F; Departament of Organic and Inorganic Chemistry (Chemistry of Coordination Research Group), Faculty of Science, University of Extremadura, Badajoz, Spain.
Pariente JA; Department of Physiology (Neuroimmunophysiology and Chrononutrition Research Group), Faculty of Science, University of Extremadura, 06006, Badajoz, Spain. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 07; Vol. 10 (1), pp. 16745. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Cell Death/*drug effects
Antineoplastic Agents/chemistry ; DNA Damage/drug effects ; HL-60 Cells ; Humans
Czasopismo naukowe
Tytuł :
Immune characterization of pre-clinical murine models of neuroblastoma.
Autorzy :
Webb ER; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK.
Lanati S; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Wareham C; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Easton A; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.; Cellular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.; Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Dunn SN; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Inzhelevskaya T; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Sadler FM; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
James S; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Ashton-Key M; Cellular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.
Cragg MS; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Beers SA; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK.
Gray JC; Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton General Hospital (MP127), Tremona Road, Southampton, Hampshire, SO16 6YD, UK. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 07; Vol. 10 (1), pp. 16695. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mice, Transgenic*
Antineoplastic Agents/*therapeutic use
Cyclophosphamide/*therapeutic use
Neuroblastoma/*immunology
Animals ; Cell Line, Tumor ; Disease Models, Animal ; Immunotherapy ; Mice ; Neuroblastoma/drug therapy ; Neuroblastoma/pathology ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.
Autorzy :
Irving E; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.
Tagalakis AD; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.; Department of Biology, Edge Hill University, Ormskirk, L39 4QP, UK.
Maeshima R; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.
Hart SL; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.
Eaton S; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.
Lehtonen A; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK.; Department of Chemistry, University of Turku, 20014, Turun yliopisto, Finland.
Stoker AW; Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 07; Vol. 10 (1), pp. 16660. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Liposomes*
Antineoplastic Agents/*administration & dosage
Neuroblastoma/*drug therapy
Vanadates/*administration & dosage
Cell Line, Tumor ; Humans ; Neuroblastoma/pathology
Czasopismo naukowe
Tytuł :
Fruticuline A, a chemically-defined diterpene, exerts antineoplastic effects in vitro and in vivo by multiple mechanisms.
Autorzy :
Corso CR; Department of Pharmacology, Biological Sciences Sector, Federal University of Parana - UFPR, PO Box 19031, Curitiba, PR, 81531-980, Brazil.; Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Stipp MC; Department of Pharmacology, Biological Sciences Sector, Federal University of Parana - UFPR, PO Box 19031, Curitiba, PR, 81531-980, Brazil.
Radulski DR; Department of Pharmacology, Biological Sciences Sector, Federal University of Parana - UFPR, PO Box 19031, Curitiba, PR, 81531-980, Brazil.
Mariott M; Postgraduate Program in Pharmaceutical Sciences, University Vale of Itajaí, Itajaí, SC, Brazil.
da Silva LM; Postgraduate Program in Pharmaceutical Sciences, University Vale of Itajaí, Itajaí, SC, Brazil.
de Souza Ramos EA; Pathology Department, Federal University of Parana, Curitiba, PR, Brazil.
Klassen G; Pathology Department, Federal University of Parana, Curitiba, PR, Brazil.
Queiroz Telles JE; Medical Pathology Department, Federal University of Parana, Curitiba, PR, Brazil.
Oliveira CS; Chemistry Department, Federal University of Parana, Curitiba, PR, Brazil.
Stefanello MÉA; Chemistry Department, Federal University of Parana, Curitiba, PR, Brazil.
Verhoeven AJ; Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
Oude Elferink RPJ; Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
Acco A; Department of Pharmacology, Biological Sciences Sector, Federal University of Parana - UFPR, PO Box 19031, Curitiba, PR, 81531-980, Brazil. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 05; Vol. 10 (1), pp. 16477. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Diterpenes/*pharmacology
Animals ; Apoptosis/drug effects ; Cell Line ; Cell Line, Tumor ; Cyclin D1/metabolism ; Female ; Fibroblasts/drug effects ; Fibroblasts/metabolism ; Hep G2 Cells ; Humans ; MCF-7 Cells ; Mice ; NF-kappa B/metabolism ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/metabolism ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Tumor Necrosis Factor-alpha/metabolism ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Tytuł :
Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.
Autorzy :
Cao L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Wang F; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Du XY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Zhu HY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Wang L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Li JY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. .; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. .; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. .
Fan L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. .; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. .; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 01; Vol. 10 (1), pp. 16357. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Paraneoplastic Syndromes/*diagnosis
Pemphigus/*diagnosis
Vidarabine/*analogs & derivatives
Adult ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Paraneoplastic Syndromes/drug therapy ; Pemphigus/drug therapy ; Prednisone/therapeutic use ; Prognosis ; Retrospective Studies ; Rituximab/therapeutic use ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells.
Autorzy :
Park SG; Department of Life Science, The Research Center for Cellular Homeostasis, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea.
Lee D; Department of Life Science, The Research Center for Cellular Homeostasis, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea.
Seo HR; Department of Life Science, The Research Center for Cellular Homeostasis, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea.
Lee SA; Department of Life Science, The Research Center for Cellular Homeostasis, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea.; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892-4263, USA.
Kwon J; Department of Life Science, The Research Center for Cellular Homeostasis, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 01; Vol. 10 (1), pp. 16330. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Indoles/*pharmacology
Neoplasms/*drug therapy
Piperidines/*pharmacology
Proteins/*antagonists & inhibitors
Pyrimidines/*pharmacology
Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Cell Line, Tumor/drug effects ; Chromatin/drug effects ; Chromatin/metabolism ; Colonic Neoplasms/drug therapy ; Humans ; Indoles/therapeutic use ; Inhibitory Concentration 50 ; Piperidines/therapeutic use ; Pyrimidines/therapeutic use ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/metabolism
Czasopismo naukowe
Tytuł :
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Autorzy :
Qin Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jiang L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yu M; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhou X; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wang Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Gong Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Peng F; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhu J; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Liu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhou L; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lu Y; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Huang M; Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Sep 30; Vol. 10 (1), pp. 16150. Date of Electronic Publication: 2020 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*mortality
Antineoplastic Agents/*therapeutic use
B7-H1 Antigen/*metabolism
Lung/*metabolism
Lung Neoplasms/*mortality
Pemetrexed/*therapeutic use
Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/pathology ; Adult ; Aged ; Biomarkers, Tumor/metabolism ; Female ; Humans ; Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
Autorzy :
Ryu S; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Ohuchi M; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.; Department of Medical Oncology and Translational Research, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Yagishita S; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Shimoi T; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yonemori K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Fujiwara Y; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hamada A; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan. .; Department of Medical Oncology and Translational Research, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Sep 23; Vol. 10 (1), pp. 15535. Date of Electronic Publication: 2020 Sep 23.
Typ publikacji :
Journal Article
MeSH Terms :
Acetanilides/*analysis
Antineoplastic Agents/*analysis
Nanoparticles/*analysis
Neoplasms/*chemistry
Quinazolines/*analysis
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/*methods
Acetanilides/pharmacokinetics ; Animals ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Drug Carriers/analysis ; Drug Carriers/pharmacokinetics ; Male ; Mammary Neoplasms, Experimental/chemistry ; Mice ; Mice, Inbred BALB C ; Neoplasm Transplantation ; Neoplasms, Experimental/chemistry ; Quinazolines/pharmacokinetics
Czasopismo naukowe
Tytuł :
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Autorzy :
Yamashita S; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hattori N; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Fujii S; Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Yamaguchi T; Department of Medical Oncology, Musashino Red Cross Hospital, 1-26-1, Kyonan, Musashino, Tokyo, 180-8610, Japan.
Takahashi M; Department of Breast Surgery, Hokkaido Cancer Center, National Hospital Organization, Kikusui 4-2, Shiroishi-Ku, Sapporo, 003-0806, Japan.
Hozumi Y; Department of Breast and Endocrine Surgery, Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University, Tsukuba, Japan.; Department of Breast Surgery, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama, Ibaraki, 309-1793, Japan.
Kogawa T; Department of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
El-Omar O; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Liu YY; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Arai N; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Mori A; H.U. Group Innovative Cancer Laboratory, H.U. Group Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Higashimoto H; H.U. Group Innovative Cancer Laboratory, H.U. Group Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ushijima T; Division of Epigenomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. .
Mukai H; Department of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Sep 23; Vol. 10 (1), pp. 15530. Date of Electronic Publication: 2020 Sep 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*/genetics
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*genetics
Peroxisomal Multifunctional Protein-2/*genetics
Receptor, ErbB-2/*genetics
Breast Neoplasms/drug therapy ; Cell Line, Tumor ; DNA Methylation ; DNA, Neoplasm/genetics ; Female ; Gene Silencing ; Humans ; Middle Aged ; Receptor, ErbB-2/antagonists & inhibitors ; Transcriptome ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies